Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04476043 · ClinicalTrials.gov registry record · Phase 2
To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa
A Phase 2 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 209
- Enrollment target
NCT04476043 is a Phase 2 study that has completed, run by Incyte Corporation. The registered enrollment target is 209 participants.
The verdict
NCT04476043, a Phase 2 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 209 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of INCB054707 in participants with hidradenitis suppurativa over a 16-week placebo-controlled treatment period followed by a 36-week open-label extension period. All eligible participants will be invited to continue treatment for an additional 48-week Long-term extension period (also open label).
Interventions
- DRUG Placebo
- DRUG INCB054707
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 209 participants |
| Start Date | 2020-08-25 |
| Est. Completion | 2023-08-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04476043
The ClinicalTrials.gov registry entry for NCT04476043 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 209 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04476043 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04476043 about?
NCT04476043 is a clinical study titled "To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa". To evaluate the efficacy and safety of INCB054707 in participants with hidradenitis suppurativa over a 16-week placebo-controlled treatment period followed by a 36-week open-label extension period. All eligible participants will be invited to continue treatment for an additional 48-week Long-term ex...
What is the current status of trial NCT04476043?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 209 participants. The study started on 2020-08-25. Estimated completion is 2023-08-16.
What interventions are being tested in trial NCT04476043?
The interventions under investigation include: Placebo (DRUG), INCB054707 (DRUG).
Who is sponsoring clinical trial NCT04476043?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.